

b.) Amendment to the Claims:

1. (Currently Amended) A method for stabilizing an antibody in a solution, which comprises adding glycine and citric acid to the antibody in said solution.
2. (Currently Amended) The method according to Claim 1, wherein the method of stabilizing ~~an antibody is suppression of the~~ suppresses formation of a soluble association and a chemically degraded product of the antibody in a the solution.
3. (Currently Amended) A method for suppressing the formation of a soluble association of an antibody in a solution, which comprises adding glycine to the antibody in said solution.
4. (Currently Amended) A method for suppressing the formation of a chemically degraded product of an antibody in a solution, which comprises adding citric acid to the antibody in said solution.
5. (Currently Amended) The method according to any one of Claims 1 to 4, wherein concentration of the antibody ~~is at~~ in said solution is from 0.01 to 150 mg/mL.

6. (Currently Amended) The method according to any one of Claims 1 to 3, wherein concentration of ~~the glycine is at~~ glycine in said solution is from 10 to 30 mg/mL.

7. (Currently Amended) The method according to any one of Claims 1, 2 and 4, wherein concentration of ~~the citric acid is at~~ citric acid in said solution is from 0.1 to 50 mmol/L.

8. (Currently Amended) The method according to ~~any one of Claims 1 to 7,~~ Claim 2, wherein the concentration of the antibody in said solution is 0.01 to 150 mg/mL, the concentration of glycine in said solution is 10 to 30 mg/mL and the concentration of citric acid in said solution is 0.1 to 50 mg/mL, said solution further comprising a nonionic surfactant.

9. (Currently Amended) The method according to ~~any one of Claims 1 to 8~~ Claim 8, wherein the pH of the solution is within the range of 4 to 7.

10. (Currently Amended) The method according to ~~any one of Claims 1 to 9~~ Claim 9, wherein the antibody is a humanized antibody or a human antibody.

11. (Currently Amended) The method according to ~~any one of Claims 1 to 10~~ Claim 10, wherein the antibody is ~~any one of antibodies~~ an antibody to ganglioside GD3 and ~~antibodies to CC chemokine receptor 4 (hereinafter referred to as CCR4)~~ or an antibody to CCR4.

12. (Currently Amended) A solution-type antibody preparation in ~~which formation of a soluble association of the antibody is suppressed~~, comprising ~~glycine and the antibody~~, and an effective amount of glycine to suppress formation of a soluble association of said antibody.

13. (Currently Amended) A solution-type antibody preparation in ~~which formation of a chemically degraded product of the antibody is suppressed~~, comprising ~~citric acid and the antibody~~, and an effective amount of citric acid to suppress formation of a chemically degraded product of said antibody.

14. (Currently Amended) A solution-type antibody preparation in ~~which formation of a soluble association, a chemically degraded product and an insoluble aggregate of the antibody are suppressed~~, comprising ~~glycine, citric acid and the antibody~~,

and an effective amount of glycine and citric acid to suppress formation of a soluble solution, a chemically degraded product and an insoluble aggregate of the antibody.

15. (Currently Amended) The preparation according to any one of Claims 12 to 14, wherein the antibody concentration is ~~at~~ 0.01 to 150 mg/mL.

16. (Currently Amended) The preparation according to ~~any one of~~ Claims 12, 14 and 15 Claim 15, wherein the glycine concentration is ~~at~~ 10 to 30 mg/mL.

17. (Currently Amended) The preparation according to ~~any one of~~ Claims 13 to 15 Claim 15, wherein the citric acid concentration is ~~at~~ 0.1 to 50 mmol/L.

18. (Currently Amended) The preparation according to ~~any one of~~ Claims 12 to 17 Claim 16, wherein the citric acid concentration is 0.1 to 50 mmol/L, and further comprising a nonionic surfactant.

19. (Currently Amended) The preparation according to ~~any one of~~ Claims 12 to 18 Claim 18, wherein the pH of the solution is ~~in the range of~~ from 4 to 7.

20. (Currently Amended) The preparation according to ~~any one of Claims 12 to 19~~ Claim 19, wherein the antibody is a humanized antibody or a human antibody.

21. The preparation according to ~~any one of Claims 12 to 20~~ Claim 20, wherein the antibody is ~~any one of antibodies~~ an antibody to ganglioside GD3 ~~and antibodies or antibody~~ to CCR4.

Claims 22-25 (Cancelled).